

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226243 A1

(51) International Patent Classification:
C07K 16/36 (2006.01)

(21) International Application Number:
PCT/US2021/030900

(22) International Filing Date:
05 May 2021 (05.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/020,505 05 May 2020 (05.05.2020) US
63/169,755 01 April 2021 (01.04.2021) US

(71) Applicant: **VEGA THERAPEUTICS, INC.** [US/US];
681 Gateway Boulevard, 3rd Floor, South San Francisco,
California 94080 (US).

(72) Inventors: **PANICKER, Sandip**; c/o Vega Therapeutics,
Inc., 681 Gateway Boulevard, 3rd Floor, South San Francisco,
California 94080 (US). **ROSENTHAL, Adam David**;
c/o Vega Therapeutics, Inc., 681 Gateway Boulevard, 3rd
Floor, South San Francisco, California 94080 (US). **BYUN,**
Tony SangYoung; c/o Vega Therapeutics, Inc., 681 Gate-
way Boulevard, 3rd Floor, South San Francisco, California
94080 (US). **DONG, Quehuong Thi**; c/o Vega Therapeu-
tics, Inc., 681 Gateway Boulevard, 3rd Floor, South San
Francisco, California 94080 (US).

(74) Agent: **ROY, Madhuri** et al.; Cooley LLP, 1299 Pennsyl-
vania Ave., Suite 700, Washington, District of Columbia
20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOF

FIG. 1



(57) Abstract: Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

WO 2021/226243 A1